# Valink Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/valink-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.valinktx.com
- Total disclosed funding: $12M
- Latest round: Series A (Oct 20, 2025)
- Investors on record: 6

## About

Valink Therapeutics Ltd. is a US-based biopharmaceutical company dedicated to developing innovative antibody-drug conjugates (ADCs) that enhance cancer treatment effectiveness while protecting healthy cells.Founded in 2020 and headquartered in Cambridge, Massachusetts, Valink Therapeutics Ltd. specializes in the research and development of bispecific ADCs aimed at addressing various cancers. The company has executed 2 deals to date and recently raised USD 11.80 mn in funding, led by Redalpine and supported by investors including Hoxton Ventures and Oxford Sciences Enterprises.Valink Therapeutics focuses on innovative antibody-drug conjugates (ADCs), specifically next-generation bispecific ADCs. Utilizing their proprietary "V-Gate" approach, these products selectively target cancer cells based on molecular markers, addressing challenges in drug resistance and treatment variability. The therapeutics cater to healthcare providers managing various cancers, including colorectal cancer and non-small cell lung cancer, primarily targeting markets in the US and the UK.Valink Therapeutics generates revenue through strategic partnerships and collaborations within the biopharmaceutical sector, particularly in oncology. Their revenue model includes licensing agreements and shared research initiatives involving their products, VLN1 and VLN2, with financial milestones linked to clinical trials and regulatory approvals.Valink Therapeutics plans to leverage recent venture funding of USD 11.80 mn to enhance its oncology pipeline and expand its market presence. Focused on launching new bispecific ADC products, the company aims to penetrate additional markets, including Europe and Asia, by 2024. Their strategy emphasizes building partnerships with healthcare organizations to facilitate the adoption of their innovative therapies.

## Funding rounds

- Series A, Oct 20, 2025, $12M — Redalpine, Hoxton Ventures, Oxford Sciences Enterprises, LongeVC, p53, RV Invest

## Investors

- Redalpine (https://capitalatlas.ai/funds/redalpine) — Series A
- Hoxton Ventures (https://capitalatlas.ai/funds/hoxton-ventures) — Series A
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A
- p53 (https://capitalatlas.ai/funds/p53) — Series A
- RV Invest (https://capitalatlas.ai/funds/rv-invest) — Series A